Skip to main content
SpringerLink
Log in

Current Requirements and Emerging Trends for Labelling as a Tool for Communicating Pharmacovigilance Findings

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The labelling of prescription drugs is expected to ensure the safe use of medicines and effect changes in use if such changes are required by new safety information. However, withdrawal of drugs from the market and data about medication errors have demonstrated the limitations of labelling as a tool for risk management. Regulatory initiatives in many countries aim at increasing the usefulness and use of labelling by healthcare professionals and patients. These changes in regulations and guidelines, which parallel changes in the approach to premarketing risk assessment and pharmacovigilance, will result in a more relevant and extensive characterisation of a product’s safety profile and better international labelling consistency. But despite improvements in the format of labelling in some countries, labelling overall continues to be bound to conventional layout and restricted in its ability to meet the heterogeneous needs of its intended audience. Technological developments such as electronic prescribing and the availability of electronic decision support systems can effectively implement compliance with labelled conditions of use and safety precautions in the prescription process. It will be one of the major challenges to make labelling easily available and suitable for use in such systems. This technology, bar coding of medicines, and preventive evaluation of labelling and packaging for clarity, readability and potential confusion can also help reduce medication errors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. US Food and Drug Administration. Requirements on content and format of labelling for human prescription drugs and biologics; requirements for prescription drug product labels; proposed rule 65. Fed Regist 2000 Dec 22; 247: 81082–131

  2. US Food and Drug Administration. Draft guidance for industry: content and format of the adverse reactions section of labelling for human prescription drugs and biologics [online]. May 2000. Available from URL: http://www.fda.gov/cder/guidance/1888dft.pdf [Accessed 2004 Feb 14]

  3. US Food and Drug Administration. Safety reporting requirements for human drug and biological products; proposed rule 68. Fed Regist 2003 Mar 14; 50: 12405–97

  4. US Food and Drug Administration. Bar code label requirements for human drug products and biological products; final rule 69. Fed Reg 2004 Feb 26; 38: 9119–71

  5. US Food and Drug Administration. Evaluating drug names for similarities: methods and approaches [online]. Public Meeting June 26, 2003. Meeting transcript and presentations available from URL: http://www.fda.gov/cder/meeting/drugNaming.htm [Accessed 2004 Feb 15]

  6. PhRMA Paperless Labelling Task Force. User requirements for paperless labelling [online]. 2000 Mar 17. Available from URL: http://www.srpub.phrma.org/reports/03.17.00.user.reqs.pdf [Accessed 2004 Feb 15]

  7. Levin R. DailyMed Initiative: enhancing patient safety through accessible medication information [online]. Presentation at DIA Electronic Document Management Plenary Session, February 2003. Available from URL: http://www.fda.gov/cder/regulatory/ersr/2003_02_13_dailymed/2003_02_13_dailymed.PPT [Accessed 2004 Feb 14]

  8. US Food and Drug Administration. The Food and Drug Administration’s Strategic Action Plan: protecting and advancing America’s health: responding to new challenges and opportunities [online]. August 2003. Available from URL: http://www.fda.gov/oc/mcclellan/strategic.html#healthcare [Accessed 2004 Feb 14]

  9. European Agency for the Evaluation of Medicinal Products. Work programme for the European Agency for the evaluation of medicinal products 2004 [online]. Available from URL: http://www.emea.eu.int/pdfs/general/direct/emeawp/005803en.pdf [Accessed 2004 Feb 13]

  10. European Commission Directorate General III. Notice to applicants, Vol. 2A. Procedures for marketing authorisation [online]. Chap. 5. Variations. February 2004. Available from URL: http://www.pharmacos.eudra.org/F2/eudralex/vol-2/home.htm [Accessed 2004 Feb 14]

  11. National Health Surveillance Agency, Brazil. Resoluccao - RDC n° 140, de 29 de maio de 2003 [online]. Available from URL: http://www.anvisa.gov.br/legis/resol/2003/rdc/140_03rdc.htm [Accessed 2004 Feb 15]

  12. Minister of Health, Canada. Guidance for industry: product monograph [online]. Available from URL: http://www.hcsc.gc.ca/hpfb-dgpsa/tpd-dpt/product_monograph_e.html [Accessed 2004 Feb 15]

  13. Japan Pharmaceutical Manufacturers Association. Pharmaceutical industry action to prevent medical accidents [online]. Available from URL: http://www.jpma.or.jp/12english/topics/topics030629_6.html [Accessed 2004 Feb 14]

  14. Japan. Bar codes to stop medicine errors [online]. Medical News Today 2004 Jan 27. Available from URL: http://www.medicalnewstoday.com/index.php?.newsid=5549 [Accessed 2004 Feb 14]

  15. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: clinical safety data management: definitions and standards for expedited reporting - E2A. October 1994 [online]. Available from URL: http://www.ich.org/MediaServer.jser?.@_ID=436&@_MODE=GLB [Accessed 2004 Feb 14]

  16. European Commission Enterprise Directorate General. Notice to Applicants, Volume 2C - regulatory guidelines [online]. Guideline on Summary of Product Characteristics. December 1999. Available from URL: http://www.pharmacos.eudra.org/F2/eudralex/vol-2/C/SPCGuidRev0-Dec99.pdf [Accessed 2004 Feb 14]

  17. Council for International Organizations of Medical Sciences. Guidelines for preparing core clinical-safety information on drugs. 2nd ed. Report of CIOMS Working Groups III and V. Geneva: Council for International Organizations of Medical Sciences, 1999

  18. European Commission Directorate General III. Notice to applicants. Vol. 2C. Regulatory guidelines: guideline on the readability of the label and package leaflet of medicinal product for human use [online]. September 1998. Available from URL: http://www.pharmacos.eudra.org/F2/eudralex/vol-2/C/gl981002.pdf [Accessed 2004 Feb 14]

  19. US Food and Drug Administration. Concept paper: premarketing risk assessment [online]. March 2003. Available from URL: http://www.fda.gov/cder/meeting/riskManageI.htm [Accessed 2004 Feb 14]

  20. Heads of Agencies Ad Hoc Working Group. Establishing a European risk management strategy: summary report of the heads of agencies ad hoc working group [online]. Available from URL: http://heads.medagencies.org/heads/docs/summary.pdf [Accessed 2004 Feb 14]

  21. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Draft consensus guideline: pharmacovigilance planning (PVP) - E2E [online]. Available from URL: http://www.ich.org/MediaServer.jser?.@_ID=1195&@_MODE=GLB [Accessed 2004 Feb 14]

  22. Goldman SA. Letter to the editor. JAMA 2002; 288(8): 956–7

    PubMed  Google Scholar 

  23. Japan Pharmaceutical Manufacturers Association. Pharmaceutical administration and regulations in Japan. March 2003 [online]. Available from URL: http://www.jpma.or.jp/12english/parj/index. [Accessed 2004 Feb 14]

  24. EMEA. EMEA/CPMP Working Group with patient Organizations. Outcome of discussions, recommendations and proposals for action [online]. London, Apr 24, 2004. Doc. ref.EMEA/CPMP/5819/04/Final Available from URL: http://www.emea.eu.int/pdfs/human/patientgroups/581904.pdf [Accessed 2004 Apr 30]

  25. Drugs@FDA web site [online]. Available at URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [Accessed 2004 Feb 14]

  26. European Public Assessment Report (EPAR) for products [online]. Available from URL: http://www.emea.eu.int/index/indexh1.htm [Accessed 2004 Feb 14]

  27. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12: 17–29

    Article  PubMed  Google Scholar 

  28. Pharmaceutical Research and Manufacturers of America. Comments of the pharmaceutical research and manufacturers of America on the food and drug administration’s proposed rule on requirements on content and format of labelling for human prescription drugs and biologics; requirements for prescription drug product labels. June 2001 [online]. Available from URL: http://www.srpub.phrma.org/fda.responses.html [Accessed 2004 Feb 14]

  29. Sless D, Wiseman R. Writing about medicines for people. 2nd ed. Canberra: Pharmaceutical Benefits Branch, Department of Health and family Services, 1997

    Google Scholar 

  30. Kahn SN. Can MedDRA be used for labelling? Should it? Presented at the Drug Information Association (DIA) Annual Meeting, Jun 1999, Baltimore (MD)

  31. Thomas MR, Holquist C, Phillips J. Med error reports to FDA show a mixed bag. FDA Safety Page [online]. Drug Topics 2001 Oct 1; 145(19): 23–4. Available from URL: http://www.fda.gov/cder/dr~g/MedErrors/reports.htm [Accessed 2004 Feb 15]

    Google Scholar 

  32. Institute for Safe Medication Practices. International Medication Error Reporting Programs [online]. Available from URL: http://www.ismp.org/Pages/mederr_intl.html#errlist [Accessed 2004 Feb 15]

  33. US Food and Drug Administration. Concept paper: risk management programs [online]. March 2003. Available from URL: http://www.fda.gov/cder/meeting/riskManageII.htm [Accessed 2004 Feb 14]

  34. Buckley M. Improving drug prescribing practices in the outpatient setting: a market analysis. California HealthCare Foundation [online]. October 2002. Available from URL: http://www.chcf.org/documents/ihealth/ImprovingDrugPrescribing.pdf [Accessed 2004 Feb 14]

    Google Scholar 

  35. ABDA Interactions Data Base - Datasheet. German Institute of Medical Documentation and Information [online]. Available from URL: http://www.dimdi.de/de/db/dbinfo/dbmemo/ai00ger.html#datenfelder [Accessed 2004 Feb 14]

  36. Oren E, Shaffer ER, Guglielmo J. Impact of emerging technologies on medication errors and adverse drug events. Am J Health Syst Pharm 2003; 60(14): 1447–58

    PubMed  Google Scholar 

  37. Covert-Kimmel K, Sensmeier J. A White paper: technological approach to enhancing patient safety. healthcare Information Management and Systems Society 2002 [online]. Available from URL: http://www.himss.org/content/files/whitepapers/patient_safety.pdf [Accessed 2004 Apr 30]

Download references

Acknowledgements

The views expressed in this article are those of the author. The manuscript was prepared during the course of the author’s usual employment with Wyeth. No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Wyeth Research, Collegeville, Pennsylvania, USA

    A. Leander Fontaine

Authors
  1. A. Leander Fontaine
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Wyeth Research, 500 Arcola Road, PO Box 8299, Philadelphia, PA 19101, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fontaine, A.L. Current Requirements and Emerging Trends for Labelling as a Tool for Communicating Pharmacovigilance Findings. Drug-Safety 27, 579–589 (2004). https://doi.org/10.2165/00002018-200427080-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427080-00009

Keywords

Search

Navigation